Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Feb 09, 2015
“The question this study asked was: Can you end up transcending the poor prognosis associated with widespread disease distribution by using radical surgery to ultimately leave that person with no disease after you've finished? . . ."
Feb 02, 2015
A new study in the Journal of Oncology Practice (JOP) set out to see how often fertility discussions were being documented in eligible patients’ charts.
Jan 26, 2015
"Often people have many questions and fears about the radiotherapy machine and treatment in general. Physicians . . . know that if the patient is anxious, there’s a strong chance it will continue throughout the therapy. It might even have clinical impact in that  . . ."
Jan 12, 2015
"The phase II study found that patients who received the immunotherapy GVAX—which is administered with cyclophosphamide—plus immunotherapy CRS-207 had a significantly longer overall survival (OS) of 6.1 months, compared to an OS of 3.9 month among patients who received GVAX alone . . ."
Jan 05, 2015
A study in the Journal of Oncology Practice identified several building blocks that are essential in shifting a cancer center towards a more interdisciplinary model [and] offers a blueprint for other hospitals that wish to start multidisciplinary clinics.
Jan 05, 2015
By Larissa Nekhlyudov, MD, MPH, and Ann Partridge, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School
Dec 29, 2014
The study found that when the score from the urinary PCA3 biomarker was considered alongside the PSA score, it resulted in a more refined measurement of risk for than could be provided with PSA alone, for both general cancer and high-grade cancer.
Dec 22, 2014
The study found that caregivers whose children or charges experienced five or more unexpected hospitalizations during the first to fifth year after diagnosis, and caregivers who had quit or changed jobs within that same time period reported a significantly higher financial burden . . .
Dec 15, 2014
“The takeaway message from our study is that the colorectal cancer survivors who both watched less TV and did more exercise had the lowest mortality compared to those who watched more TV and did less exercise.”
Dec 08, 2014
A phase II, multicenter study published in the Journal of Clinical Oncology (JCO) found that patients with pancreatic neuroendocrine tumors who were treated with combined mTOR inhibitor temsirolimus and VEGF-A monoclonal antibody bevacizumab showed a response rate (RR) of 41%, meaning that tumors shrank in 23 out of the 56...

Pages